Matthew Erick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara®, in the United States of America.

Earlier in 2023, over 70 Emerging Markets were integrated in July, the North American business transitioned in September and the European business in November, , Biocon Biologics

Bengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the Company has completed the integration of the acquired biosimilars business from Viatris in North America...

Biocon Biologics has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1 official statement said on Wednesday.To further strengthen its leadership ...

In the Apr-Jun quarter of the fiscal year, Biocon’s biosimilar division emerged as the driving force behind its top-line expansion